Loading…
← CockpitCompetitor Analysis › NTLA Intellia Therapeutics, Inc.Open in the cockpit ↗

Intellia Therapeutics, Inc.NTLACompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops in-vivo CRISPR gene-editing therapies designed to permanently edit genes inside the body for genetic diseases.

Momentum weak 24
Mkt cap
$1.37B
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$53.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-105.9 pp
WACC 13.0%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · USD$9.77
1D-0.1%
1W-14.4%
1M-17.5%
3M-21.5%
6M-20.3%
YTD+8.7%
1Y+15.2%
ATR %8.4%
Beta2.32
52w lowhigh47.1% off high

What Intellia Therapeutics does

Develops in-vivo CRISPR gene-editing therapies designed to permanently edit genes inside the body for genetic diseases.

No medicine is on the market, so cash comes from selling shares and from Regeneron, which shares development costs and, if approved, profit on NTLA-2001, a one-time infusion meant to switch off a disease-causing gene. NTLA-2002 is wholly owned, so Intellia would keep its profit.

Products and services

  • NTLA-2001 (transthyretin amyloidosis, with Regeneron)
  • NTLA-2002 (hereditary angioedema)

Customers

  • Cardiologists/hematologists (post-approval)
  • Regeneron (partner)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • In-vivo CRISPR gene editing

What could go right

  • Pivotal trial data readouts
  • Regeneron partnership milestones

What could go wrong

  • Clinical trial and manufacturing risk
  • Gene-editing field competitive and patent disputes

Moat: narrow (IP / patents, process know-how). Among the first to demonstrate in-vivo CRISPR editing in humans, with foundational patents and a Regeneron partnership.

Headquarters: Cambridge, Massachusetts, US · Founded: 2014 · Employees: 377

Named competitors

Intellia Therapeutics at a glance

Size Intellia Therapeutics (NTLA) is a United States Health Care company (Biotechnology) with a market value of $1.37B, the 2033rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $9.77 on 18 Nov 2026.

Performance Over six months the shares fell 20.3%, against -17.2% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 19 in its peer set.

Growth Revenue fell 8.1% over the last twelve months (peer median +28.0%); the operating margin is -821.2% (peer median -178.1%).

Valuation It trades at 21.3× enterprise value to sales against a peer median of 31.7× (9th cheapest of 18).

Capital Return on invested capital runs 105.9 points below its cost of capital (13.0% WACC).

Short interest Short interest is 31.6% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026Peer median 80NTLA 79
Six months, rebased to 100: Intellia Therapeutics against the median of its 20 peers (local-currency closes).

Intellia Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$52.9M$67.7M$57.9M$36.3M$52.1M
Revenue growth—+17%+60%-30%—
Gross profit$40.6M$51.7M$47.6M$27.3M$44.5M
EBITDA-$422M-$425M-$524M-$506M-$451M
Net income-$426M-$413M-$519M-$481M-$474M
Free cash flow-$358M-$396M-$355M-$408M-$347M
Capital expenditure$2.90M$1.13M$5.78M$14.0M$13.6M
Total debt$230M$93.3M$210M$115M$131M

Quarterly statements and history in the cockpit →

Intellia Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-25%0%+25%+50%4588688185RAPPTYRAANABNUVBABSIQURE688105NVAXIMCR688765MSB087010NTLA6-month return →1-month return →
Up and to the right = strong over both horizons. Intellia Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×250×500×750×4588688185ANABNUVBABSI688806QURETSHA688765MSB087010NTLARevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Intellia Therapeutics is the large dot.

Intellia Therapeutics competitors and peer comparison

Head to head with its named competitors (NTLA vs CRSP vs BEAM)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Intellia Therapeutics NTLA$1.37B-20%-8%-821%21.3×n/a
CRISPR Therapeutics CRSP$3.90B-17%-34%-2,059%95.6×n/a
Beam Therapeutics BEAM$2.17B-22%+163%-268%9.4×n/a

How Intellia Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Intellia Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureNTLAPeer medianRank in peer set
1-month return-17.5%-14.8%7th lowest of 21
6-month return-20.3%-17.2%8th lowest of 19
Distance from 52-week high-47.1%-46.1%10th lowest of 21
Revenue growth (TTM)-8.1%+28.0%5th lowest of 18
Operating margin-821.2%-178.1%6th lowest of 19
EV / Sales21.3×31.7×9th cheapest of 18
ROIC minus cost of capital-105.9 pp-17.3 pp2nd lowest of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%21.3×n/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%408.9×n/an/a
CanSino Biologics 688185.SSChina$1.38B0%+30%-4%6.6×n/an/a
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%50.1×n/an/a
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%7.9×0.5%+25.6%
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%31.7×n/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%5.7×n/an/a
Absci ABSIUnited States$1.41B+65%-47%-9,155%835.7×n/an/a
Zhuhai Trinomab Pharmaceutical 688806.SSChina$1.32Bn/a+238%-1,196%164.8×n/an/a
uniQure QUREUnited States$1.42B-17%+28%-1,027%65.4×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%4.9×39.4%-2.5%
Novavax NVAXUnited States$1.31B-14%-61%-17%2.4×n/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%2.3×n/an/a
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%170.1×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%205.0×n/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%6.3×n/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%n/an/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%12.8×n/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%359.6×n/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a

Questions

Who are Intellia Therapeutics's main competitors?
Named competitors: CRISPR Therapeutics (CRSP), Beam Therapeutics (BEAM), Verve Therapeutics (private or unlisted). The cockpit's measured peer set (industry) also includes Oncolys BioPharma (4588.T), CanSino Biologics (688185.SS), Rapport Therapeutics (RAPP), Tyra Bioscience (TYRA), AnaptysBio (ANAB), Generate Biomedicines (GENB).
Is Intellia Therapeutics expensive compared with its peers?
On ev / sales it trades at 21.3× against a peer median of 31.7×, 9th cheapest of 18 in its peer set.
How has Intellia Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -20.3% against -17.2% for the median peer; over one year +15.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.